Humana Inc (NYSE:HUM) – Oppenheimer increased their Q2 2018 EPS estimates for Humana in a research note issued to investors on Wednesday. Oppenheimer analyst M. Wiederhorn now expects that the insurance provider will post earnings of $4.12 per share for the quarter, up from their previous forecast of $3.46. Oppenheimer has a “Outperform” rating and a $305.00 price objective on the stock. Oppenheimer also issued estimates for Humana’s Q3 2018 earnings at $3.99 EPS, Q4 2018 earnings at $2.44 EPS, FY2018 earnings at $13.73 EPS, Q1 2019 earnings at $3.82 EPS, Q2 2019 earnings at $4.91 EPS, Q3 2019 earnings at $4.77 EPS and FY2019 earnings at $16.50 EPS.
Several other research firms have also recently weighed in on HUM. Leerink Swann lifted their price objective on Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $297.00 price objective on the stock in a report on Monday, January 15th. Credit Suisse Group cut their target price on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research note on Friday, November 10th. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, February 7th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $270.47.
Humana (NYSE HUM) opened at $268.07 on Monday. Humana has a 1-year low of $203.36 and a 1-year high of $293.35. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $36,767.10, a PE ratio of 16.07, a PEG ratio of 1.45 and a beta of 0.93.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business had revenue of $13.19 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter in the previous year, the business posted $2.34 EPS. Humana’s revenue for the quarter was up 2.4% on a year-over-year basis.
Several large investors have recently bought and sold shares of HUM. WFG Advisors LP increased its position in shares of Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in shares of Humana during the 3rd quarter worth approximately $115,000. American Beacon Advisors Inc. acquired a new position in shares of Humana during the 4th quarter worth approximately $122,000. ClariVest Asset Management LLC acquired a new position in shares of Humana during the 3rd quarter worth approximately $144,000. Finally, YorkBridge Wealth Partners LLC increased its position in shares of Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after purchasing an additional 297 shares during the last quarter. 94.13% of the stock is currently owned by hedge funds and other institutional investors.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the transaction, the vice president now directly owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. Insiders sold a total of 10,115 shares of company stock worth $2,501,627 in the last 90 days. Company insiders own 0.80% of the company’s stock.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a $0.50 dividend. This is a boost from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.75%. Humana’s payout ratio is presently 9.59%.
Humana declared that its board has authorized a stock buyback program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/brokers-set-expectations-for-humana-incs-q2-2018-earnings-hum.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.